All In MedTech

Device Trial Radar · NCT04088071

Real-world Experience of Catheter Ablation for the Treatment of Arrhythmias

Real-world Experience of Catheter Ablation for the Treatment of Arrhythmias Symptomatic Using Novel CARTO Technologies: REAL Registry

Last checked: Nov 20, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20,000

Planned (sponsor's estimate)

Start

Jan 1, 2018

Primary completion

Dec 31, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Heart Rhythm Clinical and Research Solutions, LLCAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Biosense Webster, Inc.
First posted
Sep 12, 2019

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this Registry is to assess procedural safety and long-term effectiveness of catheter ablations in the treatment of subjects with PAF, PsAF, and VA. The Registry will utilize real world clinical data obtained from the use of commercially available CARTO™ technologies under the authority of a health care practitioner within a legitimate practitioner-subject relationship. Data from the registry will be used to assess clinical outcomes, including procedural efficiency, safety, and long-term effectiveness of catheter ablation with novel technologies for arrhythmia patients.

Conditions

  • Paroxysmal Atrial Fibrillation
  • Persistent Atrial Fibrillation
  • Ventricular Arrhythmia

Interventions

  • Catheter ablationDevice

    Ablation using Biosense Webster, Inc. (BWI) CARTO™ technologies (e.g., THERMOCOOL SMARTTOUCH® SF, QDOT MICRO™, VARIPULSE™). Future new Biosense Webster, Inc. technologies, including new thermal and/or pulsed field ablation (PFA), may be included as they become commercially available.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Effectiveness at 90 daysTime frame: 90 days
  2. Effectiveness at 12 monthsTime frame: 12 months
  3. Long-term SafetyTime frame: 30 days post ablation

Locations

75 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • Grandview Medical Center

    Birmingham, Alabama · Recruiting

  • Cardiology Associates of Mobile

    Mobile, Alabama · Recruiting

72 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.